Table 3 Treatment-related adverse events during treatment with immune checkpoint inhibitors.

From: Longitudinal assessment of health-related quality of life in Japanese patients with advanced urothelial carcinoma receiving immune check point inhibitors

Treatment-related adverse events #

Overall (n = 42)

Pembrolizumab (n = 19)

Maintenance avelumab (n = 13)

Adjuvant nivolumab (n = 10)

Grade 2 ≤

Grade 3 ≤

Grade 2 ≤

Grade 3 ≤

Grade 2 ≤

Grade 3 ≤

Grade 2 ≤

Grade 3 ≤

Any ##

23 (55%)

4 (9.5%)

9 (47%)

2 (11%)

7 (54%)

1 (7.7%)

7 (70%)

0

Myelosuppression

1 (2.4%)

0

0

0

1 (7.7%)

0

0

0

Gastrointestinal disorder

3 (7.1%)

0

1 (5.3%)

0

1 (7.7%)

0

1 (10%)

0

Fatigue

1 (2.4%)

1 (2.4%)

1 (5.3%)

1 (5.3%)

0

0

0

0

Hepatotoxicity

2 (4.8%)

0

2 (11%)

0

0

0

0

0

Dermatoxicity

7 (17%)

1 (2.4%)

2 (11%)

0

4 (31%)

1 (7.7%)

1 (10%)

0

Interstitial lung disease

4 (9.5%)

0

3 (16%)

0

0

0

1 (10%)

0

Colitis

2 (4.8%)

0

1 (5.3%)

0

0

0

1 (10%)

0

Endocrine disorders

10 (24%)

2 (4.8%)

5 (26%)

1 (5.3%)

1 (7.7%)

0

4 (40%)

1 (10%)

Type 1 diabetes

1 (2.4%)

0

0

0

1 (7.7%)

0

0

0

  1. No patients had grade 4 ≤ adverse events during the treatment.
  2. # Determined by the investigator to be drug related; ## A patient with multiple adverse events is counted one.